



Branka Zukic

Nationality: Serbian **Date of birth:** 22/4/1976 **Phone number:** (+381) 113976445

Email address: branka.zukic@imgge.bg.ac.rs

Work: Vojvode Stepe 444a, 11042 Belgrade (Serbia)

WORK EXPERIENCE

Full Research Proffesor

Institute of Molecular Genetics and Genetic Engineering, Unoversitz of Belgrade

City: Belgrade

Country: Serbia

EDUCATION AND TRAINING

PhD

Faculty of Biology, University of Belgrade

City: Belgrade

Country: Serbia

Website: www.bio.bg.ac.rs

Semi-master course: Bioinformatics for biologists.

The School of Computing, Union University [2019 – 2021]

City: Belgrade

Website: <https://raf.edu.rs/>

LANGUAGE SKILLS

Mother tongue(s): **Serbian**

PROJECTS

Pharmacogenomics Hub in a strengthened IMGGE (PharmGenHUB)

[1/7/2022 – 30/6/2025]

Coordinator, HORIZON-WIDERA-2021-ACCESS-02-01: 101059870

Link: www.pharmgenhub.rs

THE IMPORTANCE OF PRECISION MEDICINE IN ONCOLOGY - RELATED COSTS AND CLINICAL OUTCOMES IN NSCLC PATIENTS IN AN ADVANCED PHASE OF THE DISEASE IN SERBIA

[2022 – Current]

Coordinator, IIS funded by Roche

Employing High Performance Computing System for Building up a Germline Variant Calling Pipeline for Human Whole Genome Data (EPICENTER)

[2022 – 2023]

Participant, National Initiatives for Open Science (NI4OS),

Design of the Platform for Predictive Pharmacogenomic Testing in Serbia

[2019 – 2019]

Coordinator, Innovation Voucher Program 2019, Innovation Fund, Republic of Serbia

Rare diseases: Molecular Pathophysiology, Diagnostic and Therapeutic Modalities and Social, Ethical and Legal Aspects

[2011 – 2019]

Participant in WP2 “Pharmacogenetics in pediatric hematology: individualization of therapy in pediatric acute lymphoid leukemias investigated individualization of therapy for pediatric ALL patients using pharmacogenomics principles”, Ministry of Education, Science and Technological Development, Republic of Serbia (III41004)

Strengthening the Research Potential of IMGGE through Reinforcement of Biomedical Science of Rare Diseases in Serbia – en route for innovation

[2013 – 2016]

Leader of WP2A „Reinforcement of material resources and implementation of new approaches for IMGGE research progress“, EU-FP7-REGPOT (316088)

Pharmacogenomic Markers in Immunosuppressive and Immunomodulating Therapy: From the Validated Markers to Genotyping Kits and Clinical Algorithms

[2014 – 2015]

Serbian team leader of a bilateral project between the Republic of Serbia and the Republic of Slovenia, 451-03-3095/2014-09/45

Design of a genetic test to improve male reproductive health

[2019 – 2019]

Coordinator, Innovation Voucher Program 2019, Innovation Fund, Republic of Serbia

Health Improvement in Serbia through Reinforcement of Biomedical Science and Technology (HISERBS)

[2006 – 2009]

Participant, EU FP6 SSA INCO-026357

Researchers night “SCIMFONICOM 2014-2015”

[2014 – 2015]

EU, CSA-SA, FP7-PEOPLE-2012-NIGHT-633376

Researchers night Science in Motion for Friday Night Commotion – SCIMFONICOM

[2012 – 2013]

FP7-PEOPLE-2012-Night, 609724

Little school of DNAlogy

[2009 – 2014]

Participant, Ministry of Education and Science (2009, 2010), Center for the Promotion of Science (2011, 2012, 2013, 2014)

Little school of DNAlogy

[2020 – 2020]

Coordinator, Center for the Promotion of Science

HONOURS AND AWARDS

The best PhD thesis in the field of molecular biology for 2010.

Goran Ljubijankic Foundation [2011]

Write here the description...

NETWORKS AND MEMBERSHIPS

Serbian Genetic Society

[2011 – Current]

The Serbian Society for Molecular Biology (MolBioS)

[2011 – Current]

Serbian Society for Bioinformatics and Computational Biology (BIRBI)

[2022 – Current]

Serbian Biological Society

[2011 – Current]

PUBLICATIONS

[Can Pharmacogenetic Variants in TPMT, MTHFR and SLCO1B1 Genes Be Used as Potential Markers of Outcome Prediction in Systemic Sclerosis Patients?](#)

[2023]

Jelovac M, et al Int J Mol Sci. 2023 May 10;24(10):8538.

[Germline Variants in Cancer Predisposition Genes in Pediatric Patients with Central Nervous System Tumors.](#)

[2023]

Jovanović A et al. Int J Mol Sci. 2023 Dec 12;24(24):17387.

[The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress.](#)

[2023]

van Schaik RH et al. Pharmacogenomics. 2023 Apr;24(5):243-246.

[Diagnostic and Therapeutic Implications of Long Non-Coding RNAs in Leukemia](#)

[2022]

Gasic V et al. Life (Basel). 2022 Nov 2;12(11):1770.

[Genome-Wide Association Study of COVID-19 Outcomes Reveals Novel Host Genetic Risk Loci in the Serbian Population.](#)

[2022]

Zecevic M et al. Front Genet. 2022 Jul 14;13:911010.

[Machine Learning Modeling from Omics Data as Prospective Tool for Improvement of Inflammatory Bowel Disease Diagnosis and Clinical Classifications](#)

[2021]

Stankovic B et al. Genes (Basel). 2021 Sep 18;12(9):1438.

[The first insight into the genetic structure of the population of modern Serbia](#)

[2021]

Drljaca T et al. Sci Rep. 2021 Jul 7;11(1):13995.

[Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients.](#)

Pavlovic D et al. Diagnostics (Basel). 2021 Dec 30;12(1):86.

[Association of Vitamin D, Zinc and Selenium Related Genetic Variants With COVID-19 Disease Severity.](#)

[2021]

Kotur N et al. Front Nutr. 2021 Jun 4;8:689419.

[The FKBP5 genotype and childhood trauma effects on FKBP5 DNA methylation in patients with psychosis, their unaffected siblings, and healthy controls](#)

[2021]

Mihaljevic M et al. Psychoneuroendocrinology. 2021 Jun;128:105205.

[Clinical Application of Thiopurine Pharmacogenomics in Pediatrics](#)

[2020]

Pavlovic S et al. Curr Drug Metab. 2020;21(1):53-62.

[Analysis of the promoter regions of disease-causing genes in maturity-onset diabetes of the young patients.](#)

[2020]

Komazec J et al. Mol Biol Rep. 2020 Sep;47(9):6759-6768.

[Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment](#)

[2020]

Kotur N et al. Genes (Basel). 2020 Apr 24;11(4):468.

[Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations](#)

[2020]

Stanković B et al. J Med Biochem. 2020 Oct 2;39(4):488-499.

[Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection](#)

[2020]

Klaassen K et al. Infect Genet Evol. 2020 Oct;84:104498.

[Exploring inflammatory and apoptotic signatures in distinct Crohn's disease phenotypes: Way towards molecular stratification of patients and targeted therapy](#)

[2020]

Stankovic B et al. Pathol Res Pract. 2020 Jun;216(6):152945

DRIVING LICENCE

Driving Licence: B